Biblio
Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023.
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience. Ann Hematol. 2023.
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission. Eur J Haematol. 2023.
Mutational Profile, Outcomes, and Impact of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and Inconclusive Cytogenetic Analysis. Eur J Haematol. 2023.
Propensity score matching analysis comparing the efficacy and steroid tapering benefit of extracorporeal photopheresis to best available therapy in third-line or beyond treatment for chronic GvHD. Transplant Cell Ther. 2023.
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes. Hematol Oncol Stem Cell Ther. 2023;17(1):60-71.
Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality. Support Care Cancer. 2023;31(10):564.
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors. Eur J Haematol. 2021.
ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2021.
Fresh versus Frozen Allogeneic Peripheral Blood Stem Cell Grafts: a Successful Timely Option. Am J Hematol. 2020.
Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. Eur J Haematol. 2019.